KDCA Signs Procurement Contract for 12.07 Million Doses of Influenza Vaccine

On-site Inspections of Storage Facilities and Transport Equipment Planned

The Korea Disease Control and Prevention Agency (KDCA) announced on June 9 that it has signed a procurement contract for 12.07 million doses of vaccine required for the '2025-2026 Influenza National Immunization Support Program.'

Yonhap News Agency

The quantity to be purchased was determined by taking into account the actual number of vaccinations administered during the previous season (2024-2025), the target vaccination rate for the upcoming season (2025-2026), and the results of demand surveys conducted by local governments.

Six companies were selected as vaccine suppliers in order of the lowest price offered through a public notice by the Public Procurement Service: Sanofi-Aventis Korea, Boryung Biopharma, GC, SK Bioscience, Korea Vaccine, and Ilyang Pharmaceutical. The contract price was set between 9,339 and 9,660 won per dose (including distribution costs and value-added tax).

Ji Youngmi, Commissioner of the KDCA, stated, "We will do our utmost to ensure safe immunization by conducting thorough on-site inspections of storage facilities and transport equipment (including transport containers and vehicles) for the contracted suppliers prior to vaccine delivery."